|
ITPRIPL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62314606200198E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.71671574125776E-12 |
| Normal-vs-Stage2 |
9.661200E-03 |
| Normal-vs-Stage3 |
5.40760003442387E-09 |
| Normal-vs-Stage4 |
1.78850000032149E-07 |
| Stage1-vs-Stage2 |
4.071600E-02 |
| Stage1-vs-Stage3 |
7.738600E-01 |
| Stage1-vs-Stage4 |
6.318000E-01 |
| Stage2-vs-Stage3 |
4.672100E-02 |
| Stage2-vs-Stage4 |
3.377600E-02 |
| Stage3-vs-Stage4 |
8.220000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.6983081607691E-12 |
| Normal-vs-AfricanAmerican |
1.393650E-04 |
| Normal-vs-Asian |
3.82429998779799E-09 |
| Caucasian-vs-AfricanAmerican |
5.222600E-01 |
| Caucasian-vs-Asian |
2.335600E-01 |
| AfricanAmerican-vs-Asian |
8.203600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.68249999990644E-08 |
| Normal-vs-Female |
1.01696429055664E-13 |
| Male-vs-Female |
1.665200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.42916797787984E-13 |
| Normal-vs-Age(41-60Yrs) |
6.1651994620604E-10 |
| Normal-vs-Age(61-80Yrs) |
1.86732999999384E-05 |
| Normal-vs-Age(81-100Yrs) |
1.211820E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.950000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.026400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.402400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.020200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.943200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.262800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.077200E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
2.462200E-02 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
6.89409995757728E-09 |
| Tall-VS-Other |
1.662100E-02 |
| Tall-VS-Normal |
1.1474999994654E-07 |
| Follicular-VS-Other |
5.864800E-01 |
| Follicular-VS-Normal |
9.071800E-01 |
| Other-VS-Normal |
6.646200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.14939999995567E-06 |
| Normal-vs-N1 |
1.17410000000095E-06 |
| N0-vs-N1 |
2.783600E-02 |
|
|
